You are here

  • Home
  • Archive
  • Volume 15, Issue Suppl 1
  • E-002 Procedural, clinical and safety outcomes in acute ischemic stroke stratified by operator techniques and clot location – insights from the ASSIST registry

Article Text

Article menu

Download PDFPDF

SNIS 20th annual meeting electronic poster abstracts
E-002 Procedural, clinical and safety outcomes in acute ischemic stroke stratified by operator techniques and clot location – insights from the ASSIST registry
Free
  1. R Gupta1,
  2. D Vollherbst2,
  3. S Miralbés3,
  4. B Naravetla4,
  5. A Spiotta5,
  6. C Loehr6,
  7. M Martínez-Galdámez7,
  8. R McTaggart8,
  9. L Defreyne9,
  10. P Vega10,
  11. O Zaidat11,
  12. L Price12,
  13. D Liebeskind13,
  14. M Möhlenbruch2
  1. 1Neurosurgery, Wellstar Health System, Marietta, GA, USA
  2. 2Uniklinik Heidelberg, Heidelberg, Germany
  3. 3Hospital Son Espases, Mallorca, Spain
  4. 4McLaren Regional Medical Center, Flint, MI, USA
  5. 5Medical University of South Carolina, Charleston, SC, USA
  6. 6Klinikum Vest Recklinghausen, Recklinghausen, Germany
  7. 7Hospital Clínico Universitario de Valladolid, Valladolid, Spain
  8. 8Rhode Island Hospital, Providence, RI, USA
  9. 9Ghent University Hospital, Ghent, Belgium
  10. 10Hospital Universitario Central de Asturias-HUCA, Oviedo, Spain
  11. 11Neuroscience Department, Bon Secours Mercy Health St. Vincent Medical Center, Toledo, OH, USA
  12. 12Stryker Neurovascular, Fremont, CA, USA
  13. 13Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

Abstract

Background and Aims The ASSIST registry is a prospective, global registry that assessed clinical and procedural outcomes associated with various operator techniques for mechanical thrombectomy (MT) in acute ischemic stroke (AIS) patients with large vessel occlusion (LVO) where Stryker Neurovascular devices were used for the first pass. An analysis of the registry data aims to determine if procedural outcomes, including first-pass effectiveness, safety, and clinical outcomes, vary by clot location among the three MT techniques.

Methods ASSIST patients were grouped in three cohorts: Stent Retriever (SR) Classic [SR + Balloon Guide Catheter (BGC)], SR Combination [SR + Aspiration Catheter (AC) ± Pump + BCG or Long Sheath (LS)] and Direct Aspiration [AC ± Pump + BGC or LS]. The procedural endpoint of eTICI 2c or greater on the first pass was stratified by clot location (MCA-M1, MCA-M2 and ICA). Similar analyses were performed on the primary clinical endpoint (mRS 0-2 at Day 90) and other secondary and safety endpoints.

Results A total of 1492 patients met the ASSIST eligibility criteria. First pass eTICI scores across the three different techniques, stratified by clot location, will be presented. Stratification by clot location will be also provided for other procedural, clinical and safety endpoints.

Conclusions ASSIST provides insights into the effectiveness and safety of different MT techniques as stratified by clot location to improve reperfusion rates, functional outcomes, and quality of life for AIS patients worldwide. ClinicalTrials.gov ID: NCT03845491

Disclosures R. Gupta: 2; C; Rapid Medical, Vesalio. 6; C; PI, ASSIST Registry Stryker Neurovascular PI, DISTALS Study, Rapid Medical PI, RECCLAIM II study, Zoll PI, CLEAR Study, Vesalio, CEC MIND Trial Penumbra, Steering committee ELEVATE Trial, Medtronic Steering committee MEMBRANE Trial, Cerenovous. D. Vollherbst: 1; C; MicroVention (unrelated to this work). 2; C; Medtronic. 6; C; paid lectures for Cerenovus. S. Miralbés: None. B. Naravetla: None. A. Spiotta: 1; C; Stryker, Medtronic, Penumbra. 2; C; Stryker, Terumo, Penumbra, and Siemens. C. Loehr: None. M. Martínez-Galdámez: None. R. McTaggart: None. L. Defreyne: None. P. Vega: None. O. Zaidat: 1; C; Stryker, Medtronic, Cerenovus, Penumbra, and Genentech. 2; C; Cerenovus, Stryker, Penumbra, and Medtronic. 4; C; ownership interest in Galaxy Therapeutics INC. 6; C; serves on the endovascular committee as cochair for National Institutes of Health StrokeNet Consortium and has served as an expert witness. L. Price: 5; C; Principal Biostatistician at Stryker Neurovascular. D. Liebeskind: 2; C; imaging core lab for Cerenovus, Genentech, Medtronic, Rapid Medical, Stryker, Vesalio. M. Möhlenbruch: 2; C; Stryker Neurovascular.

https://doi.org/10.1136/jnis-2023-SNIS.102

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.